The 86% target precision rate is a strong technical validation of Evaxion's AI platform, which could enhance confidence in its broader pipeline. Traders should monitor the upcoming AACR presentation and anticipate potential partnership interest or follow-on clinical developments. The robust immune response data may reprice expectations for EVX-01's clinical efficacy, especially given the 75% ORR already observed.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 17 $4.45entry
- T+1 · 7mo ago +0.90%α +1.09% · $4.49
- T+5 · 7mo ago −9.44%α −9.99% · $4.03
- T+20 · 6mo ago −7.42%α −12.79% · $4.12
- T+60 · 4mo ago −31.91%α −38.05% · $3.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion A/S announced phase 2 trial data showing its AI-designed personalized cancer vaccine EVX-01 achieved an 86% success rate in triggering tumor-specific immune responses, a key validation of its AI-Immunology platform. The results, to be presented at AACR, also show durable immune responses and de novo T-cell activation, reinforcing the vaccine's therapeutic potential in advanced melanoma.
Key Facts
- 86% of vaccine targets in EVX-01 triggered a tumor-specific immune response, described as a record high
- Durable vaccine-specific immune responses observed over two years
- High de novo T-cell response rate (86%) indicates strong immune system activation
- Positive correlation between AI-prediction scores and immune response magnitude confirmed
- Trial conducted in advanced melanoma patients using EVX-01 in combination with KEYTRUDA (pembrolizumab)
- Two-year clinical data previously showed a 75% Objective Response Rate
- Three-year clinical data expected in H2 2026
Financial Impact
High potential long-term value given platform validation and lead asset advancement; no immediate financials reported
Risk Factors
- Clinical trial results do not guarantee regulatory approval
- Small market cap ($35M) increases volatility risk
- Dependence on future clinical data and external funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002532 |
| Document: f6k_041726.htm | 0001171843-26-002532 |
| Document: 0001171843-26-002532-index-headers.html | 0001171843-26-002532 |
| Document: 0001171843-26-002532-index.html | 0001171843-26-002532 |
| Document: 0001171843-26-002532.txt | 0001171843-26-002532 |
Track record
50 reports on EVAX
6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers